Skip to main content

Jetrea FDA Approval History

FDA Approved: Yes (First approved October 17, 2012)
Brand name: Jetrea
Generic name: ocriplasmin
Dosage form: Intravitreal Injection
Company: ThromboGenics NV
Treatment for: Vitreomacular Adhesion

Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

Development timeline for Jetrea

DateArticle
Oct 18, 2012Approval FDA Approves Jetrea for Symptomatic Vitreomacular Adhesion in the Eyes
Jul 27, 2012FDA Advisory Committee Recommends ThromboGenics' Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
Jul  3, 2012ThromboGenics Announces FDA Accepts Filing and Grants Priority Review to Its Biologics License Application for Ocriplasmin Intravitreal Injection
Jun  7, 2012ThromboGenics Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin
Dec 27, 2011ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA

See also

Jetrea (ocriplasmin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer